{"DataElement":{"publicId":"4382993","version":"1","preferredName":"Cancer Treatment Concurrent Administered Code Indicator","preferredDefinition":"Concurrent use of other anti-cancer therapy including chemotherapy agents, target agents, or biological agents.","longName":"CATX_CONC_ADM_IND3","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"2738396","version":"1","preferredName":"Cancer Treatment Concurrent Administered","preferredDefinition":"information related to the concurrent administration of an intervention for management of a malignant neoplasm.","longName":"CATX_CONCUR_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2738394","version":"1","preferredName":"Cancer_Treatment","preferredDefinition":"Any intervention for management of a malignant neoplasm.","longName":"C16212","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cancer Therapeutic Procedure","conceptCode":"C16212","definition":"Any intervention for management of a malignant neoplasm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"49BD3CC9-CFE5-0DB9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-03-31","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-03-31","modifiedBy":"ONEDATA","dateModified":"2008-03-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2207816","version":"1","preferredName":"Concurrent Administered","preferredDefinition":"Occurring or operating at the same time.:Given.","longName":"C25456:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Concurrent","conceptCode":"C25456","definition":"Occurring or operating at the same time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-315F-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49BD3CC9-CFF2-0DB9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-03-31","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-03-31","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"3876359","version":"1","longName":"Exclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876424","version":"1","longName":"Prior Treatments","context":"Theradex"}]},{"publicId":"3876594","version":"1","longName":"Theradex","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876603","version":"1","longName":"Theradex - CTMS 3.14","context":"Theradex"}]}],"AlternateNames":[{"name":"CATX_CONC_ADM_IND3","type":"USED_BY","context":"Theradex"},{"name":"PBTC","type":"USED_BY","context":"PBTC"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"CCTG","type":"USED_BY","context":"CCTG"},{"name":"IE_IEORRES_OTHERINVTX","type":"OID, CCTG","context":"CCTG"}],"ReferenceDocuments":[{"name":"Theradex - 1","type":"Alternate Question Text","description":"Has patient received an investigational anti-cancer drug within 28 days preceding the first dose of dabrafenib?","url":null,"context":"Theradex"},{"name":"Is the patient receiving any o","type":"Preferred Question Text","description":"Is the patient receiving any other anticancer investigational agents?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"Is patient currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Has patient received any other investigational agents less than or equal to 28 days prior to registration?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"Has patient received any other type of investigational agents within 28 days before the first dose of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"Has patient received any other approved or investigational agent less than 3 weeks prior to registration unless otherwise noted by the Protocol Chair","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"Is patient receiving any other therapies for cancer treatment (with the exception of GnRH agonists for prostate cancer)?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Patient is receiving any other anti-cancer therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Is patient receiving any other investigational agents for cancer?","url":null,"context":"Theradex"},{"name":"PBTC_Text1","type":"Alternate Question Text","description":"Is the patient receiving any other anti-cancer or investigation drug therapy?","url":null,"context":"PBTC"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"Is patient receiving any other biologic, cytotoxic or investigational agents?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"Has patient received any other investigational agent within 4 weeks prior to Cycle 1, Day 1 (or within five half-lives of the investigational product, whichever is shorter)?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Has patient received any other investigational agent within 4 weeks prior to Cycle 1, Day 1 (or within five half-lives of the investigational product, whichever is longer)?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Has patient received any other investigational agents within the past 28 days?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"Has patient received any other experimental drug or therapy within 21 days of baseline?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"Has patient received any other investigational drugs within 28 days (or five half-lives, whichever is shorter; with a minimum of 14 days from the last dose) preceding the first dose of talimogene laherparepvec (T-VEC) and during the study?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"Has patient received any other investigational agent within 4 weeks prior to Cycle 1, Day 1?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"Has patient received any investigational therapy within 4 weeks of enrollment?","url":null,"context":"Theradex"},{"name":"PBTC_Text2","type":"Alternate Question Text","description":"Is the patient receiving any other anti-cancer or investigational drug therapy?","url":null,"context":"PBTC"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"Has patient received any other investigational agent within 4 weeks prior to Cycle 1, Day 1?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"Has patient received any other investigational agents within the past 28 days prior to cycle 1 day 1?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"Has patient received any other investigational agent within 4 weeks (or within five half-lives of the investigational product, whichever is shorter) prior to Cycle 1, Day 1 (minimum of 1 week between prior therapy and study enrollment)?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"Is patient receiving any other investigational agents or anticancer therapy concurrently or within 4 weeks (i.e. 28 days)?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"Has patient received any investigational therapy within 4 weeks of study entry?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"Has patient received any other investigational agent within 3 weeks prior to Cycle 1, Day 1?","url":null,"context":"Theradex"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"Is patient receiving any other investigational agent or participated in another clinical study with an investigational product during the last 30 days or five half-lives of the drug (whichever is greater) prior to the initiation of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 28","type":"Alternate Question Text","description":"Has patient received any other investigational, chemotherapeutic or targeted drugs within 28 days (or five half-lives, whichever is shorter; with a minimum of 14 days from the last dose) preceding the first dose of talimogene laherparepvec (T-VEC) and during the study?","url":null,"context":"Theradex"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"Is patient receiving any other concurrent investigational agents?","url":null,"context":"Theradex"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"Is patient receiving any other investigational agents, concurrently?","url":null,"context":"Theradex"},{"name":"Theradex - 26","type":"Alternate Question Text","description":"Is patient receiving any other investigational agent or participated in another clinical study with an investigational product during the last 30 days or five half-lives of the drug (whichever is less) prior to the initiation of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 29","type":"Alternate Question Text","description":"Is patient concurrently participating on another clinical study with investigational medicinal product or any other investigational agents?","url":null,"context":"Theradex"},{"name":"Theradex - 30","type":"Alternate Question Text","description":"Is patient currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 31","type":"Alternate Question Text","description":"Is patient actively receiving any other investigational agents?","url":null,"context":"Theradex"},{"name":"Theradex - 32","type":"Alternate Question Text","description":"Is the patient receiving any other investigational agents or has received any other type of investigational agent within 4 weeks prior to first dose of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"Is patient receiving any other concurrent anti-cancer therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 33","type":"Alternate Question Text","description":"Is patient receiving any other investigational drugs?","url":null,"context":"Theradex"},{"name":"Theradex - 34","type":"Alternate Question Text","description":"Is patient receiving or planning to receive any investigational agents other than tocilizumab except for: investigational agents directed at a patient's underlying cancer, investigational SARS-CoV-2 anti-viral agents or convalescent serum directed at COVID-19 disease?","url":null,"context":"Theradex"},{"name":"Theradex - 35","type":"Alternate Question Text","description":"Is patient receiving or planning to receive any investigational agents other than tocilizumab except for: investigational agents directed at a patient's underlying cancer, investigational SRAS-CoV-2 anti-viral agents or convalescent serum directed at COVID-19 disease?","url":null,"context":"Theradex"},{"name":"COG CRF Text 001","type":"Alternate Question Text","description":"Is the patient receiving any other investigational agents?","url":null,"context":"COG"},{"name":"Theradex - 36","type":"Alternate Question Text","description":"Is patient receiving any other investigational agents within 28 days prior to start of treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 37","type":"Alternate Question Text","description":"Has patient received other investigational drugs within 28 days (or five half-lives, whichever is shorter; with a minimum of 14 days from the last dose) preceding the first dose of study treatment and during the study?","url":null,"context":"Theradex"},{"name":"Theradex - 38","type":"Alternate Question Text","description":"Has patient received investigational therapy less than or equal to 4 weeks or within a time interval less than at least five half-lives of the investigational agent, whichever is longer, before initiation of protocol therapy?","url":null,"context":"Theradex"},{"name":"NRG TEXT1","type":"Alternate Question Text","description":"Did the patient receive any prior investigational agent?","url":null,"context":"NRG"},{"name":"NRG CRF TEXT1","type":"Alternate Question Text","description":"If investigational agent was received within 28 days prior to registration, has it been at least 5 half lives since agent end date?","url":null,"context":"NRG"},{"name":"Theradex - 39","type":"Alternate Question Text","description":"Has patient received investigational therapy within four weeks before starting study treatment or is scheduled to receive investigational therapy during the planned treatment period?","url":null,"context":"Theradex"},{"name":"Theradex - 40","type":"Alternate Question Text","description":"Has patient received treatment with any other investigational agent within 4 weeks before initiation of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 42","type":"Alternate Question Text","description":"Is patient receiving concurrent anticancer treatment, major surgery, or use of any investigational drug within 28 days before the start of trial treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 41","type":"Alternate Question Text","description":"Is patient receiving any other investigational agents, within 30 days of the start of this trial and throughout the duration of this trial?","url":null,"context":"Theradex"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Is the patient currently receiving another investigational drug?","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"4382993","url":null,"context":"COG"},{"name":"Theradex - 43","type":"Alternate Question Text","description":"Has patient received treatment with any other agent administered for the treatment of the patient's cancer, within four half-lives or 4 weeks prior to Cycle 1, Day 1, whichever is shorter?","url":null,"context":"Theradex"},{"name":"Theradex - Corrected 43","type":"Alternate Question Text","description":"Has patient received treatment with any other agent administered for the treatment of the patient's cancer, within four half-lives or 4 weeks prior to cycle 1, Day 1, whichever is shorter?","url":null,"context":"Theradex"},{"name":"Theradex - 44","type":"Alternate Question Text","description":"Is patient concurrently receiving any other antineoplastic treatment or investigational agents?","url":null,"context":"Theradex"},{"name":"Theradex - 45","type":"Alternate Question Text","description":"Has patient received treatment with any other investigational agent within 4 weeks prior to Cycle 1, Day 1?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FDC74663-AB3A-780B-E040-BB89AD4340DA","latestVersionIndicator":"Yes","beginDate":"2014-07-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-07-09","modifiedBy":"SOKKERL","dateModified":"2023-07-19","changeDescription":"Curated new from existing 2186021.","administrativeNotes":"7/20/2022: fixed the box symbol in AQTs.wz","unresolvedIssues":null,"deletedIndicator":"No"}}